Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUTREACH: Outpatient Liso-cel in R/R LBCL
NCT03744676Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2018
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of lisocabtagene maraleucel in B-cell non-Hodgkin lymphoma, sponsored by Celgene Corporation. Started Nov 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03744676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744676.